Bank Of America Corp Cel Sci Corp Transaction History

Bank Of America Corp

$1.17 Trillion
Q4 2024

A detailed history of Bank Of America Corp transactions in Cel Sci Corp stock. As of the latest transaction made, Bank Of America Corp holds 1,655 shares of CVM stock, worth $695. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,655

Previous 14,658 88.71%

Holding current value

$695

Previous $15,000 100.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.4 - $1.11 $5,201 - $14,433	-13,003 Reduced 88.71%	1,655 $0
Q3 2024 Nov 14, 2024	SELL	$1.05 - $1.5 $15,691 - $22,416	-14,944 Reduced 50.48%	14,658 $15,000
Q2 2024 Aug 14, 2024	BUY	$1.11 - $1.85 $496 - $826	447 Added 1.53%	29,602 $34,000
Q1 2024 May 15, 2024	SELL	$1.63 - $3.08 $2,308 - $4,361	-1,416 Reduced 4.63%	29,155 $55,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $3.07 $1,658 - $4,758	-1,550 Reduced 4.83%	30,571 $83,000
Q1 2023 May 12, 2023	SELL	$2.17 - $3.13 $95 - $137	-44 Reduced 0.14%	32,121 $74,000
Q4 2022 Feb 10, 2023	SELL	$1.99 - $3.52 $6,559 - $11,601	-3,296 Reduced 9.29%	32,165 $75,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $198,059 - $335,227	-64,097 Reduced 64.38%	35,461 $110,000
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $198,750 - $384,404	-77,035 Reduced 43.62%	99,558 $448,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $263,726 - $516,716	-67,106 Reduced 27.54%	176,593 $695,000
Q4 2021 Feb 08, 2022	BUY	$7.1 - $12.82 $1.29 Million - $2.33 Million	181,425 Added 291.33%	243,699 $1.73 Million
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $282,886 - $462,467	37,027 Added 146.66%	62,274 $684,000
Q2 2021 Sep 13, 2021	BUY	$8.68 - $27.49 $219,143 - $694,040	25,247 New	25,247 $219,000

Others Institutions Holding CVM

# of Institutions

Shares Held

6.95M

Call Options Held

38.3K

Put Options Held

184K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $18.2M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Cel Sci Corp Transaction History